Amgen Inc. (SNSE:AMGN)

Market Cap	174.50T +16.1%
Revenue (ttm)	33.10T +10.0%
Net Income	6.95T +88.5%
EPS	12,817.96 +88.2%
Shares Out	n/a
PE Ratio	25.12
Forward PE	16.64
Dividend	8,965.01 (2,693.97%)
Ex-Dividend Date	Feb 13, 2026

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	332.78
Day's Range	n/a
52-Week Range	246.21 - 332.78
Beta	n/a
RSI	100.00
Earnings Date	Apr 30, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD